Bayesian Capital Management LP Invests $1.65 Million in Vaxcyte, Inc. (NASDAQ:PCVX)

Bayesian Capital Management LP bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 20,204 shares of the company's stock, valued at approximately $1,654,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of PCVX. CIBC Asset Management Inc raised its holdings in shares of Vaxcyte by 5.5% in the 4th quarter. CIBC Asset Management Inc now owns 3,307 shares of the company's stock valued at $271,000 after purchasing an additional 171 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after acquiring an additional 260 shares during the period. Catalyst Funds Management Pty Ltd raised its position in shares of Vaxcyte by 1.7% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock worth $1,506,000 after acquiring an additional 300 shares in the last quarter. Whipplewood Advisors LLC purchased a new stake in shares of Vaxcyte during the 4th quarter worth $28,000. Finally, Blue Trust Inc. grew its stake in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after purchasing an additional 371 shares during the last quarter. Institutional investors own 96.78% of the company's stock.

Vaxcyte Stock Performance

NASDAQ PCVX traded up $2.45 during trading on Thursday, reaching $31.45. The company's stock had a trading volume of 3,169,112 shares, compared to its average volume of 1,301,882. The firm has a market cap of $4.06 billion, a price-to-earnings ratio of -6.84 and a beta of 1.27. The business's fifty day moving average price is $48.25 and its 200-day moving average price is $75.86. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter in the prior year, the business posted ($0.85) EPS. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on PCVX shares. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Guggenheim reaffirmed a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Bank of America dropped their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Cantor Fitzgerald started coverage on Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating for the company. Finally, The Goldman Sachs Group dropped their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and a consensus price target of $136.50.

Insider Transactions at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares of the company's stock, valued at approximately $11,351,794.37. The trade was a 4.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.